Sunshine Biopharma (SBFM) Short term Debt (2018 - 2019)

Sunshine Biopharma (SBFM) posted Short term Debt of $27541.0 for Q3 2019, down 1.18% on a QoQ basis from $27869.0 in Q2 2019.

Sunshine Biopharma (SBFM) Short term Debt (2018 - 2019) Analysis & Trends

Sunshine Biopharma's Short term Debt history runs 2 years deep, the most recent figure standing at $27541.0 for Q3 2019.

Quarterly Short term Debt changed N/A year-over-year to $27541.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $27541.0 (changed N/A YoY) and the FY2018 annual result came in at $20871.0, changed N/A from the prior year.
Short term Debt was $27541.0 for Q3 2019 at Sunshine Biopharma, down from $27869.0 in the prior quarter.
Across five years, Short term Debt topped out at $59558.0 in Q1 2019 and bottomed at $20871.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	89.28 Bn	87.42 Bn	-
2	Teva Pharmaceutical Industries	35.97 Bn	32.23 Bn	1.97 Bn
3	Zoetis	32.42 Bn	30.48 Bn	1.62 Bn
4	Takeda Pharmaceutical	27.48 Bn	23.42 Bn	4.39 Bn
5	United Therapeutics	22.89 Bn	20.73 Bn	648.10 Mn
6	RedHill Biopharma	22.11 Bn	22.11 Bn	-
7	Viatris	20.44 Bn	18.64 Bn	1.16 Bn
8	Neurocrine Biosciences	17.76 Bn	16.44 Bn	800.70 Mn
9	Elanco Animal Health	12.62 Bn	12.19 Bn	785.00 Mn
10	Sunshine Biopharma	750,608.81	-6.16 Mn	2.18 Mn

Download Data